Abivax Sa's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Abivax Sa (ABVX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Abivax Sa vs Its Competitors
- Scale: Abivax Sa ranks #52 of 545 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.1% of industry market cap.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
API endpoints for this dataset
Abivax Sa's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Abivax Sa | - | - | - | No |
| Competitors combined (52) | ||||
| High-Confidence Competitors (7) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ABVX Stock Performance relative to its Competitors
ABVX Stock Performance relative to High-Confidence Competitors
ABVX Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Cypherpunk Technologies Inc | 282.9% | Outperformed |
| 3 | An2 Therapeutics Inc | 282.9% | Outperformed |
| 4 | 180 Life Sciences Corp | 282.9% | Outperformed |
| 5 | Vir Biotechnology Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Abivax Sa's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Abivax Sa's Comment on Competition and Industry Peers
Publicly Traded Peers of Abivax Sa
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Abivax Sa |
6,048.88 | - |
 Pfizer Inc |
168,101.73 | 63,625.00 |
 Bristol myers Squibb Company |
127,573.42 | 50,033.00 |
 Moderna Inc |
107,062.00 | 2,228.00 |
 Regeneron Pharmaceuticals Inc |
97,147.78 | 16,896.20 |
 Biontech Se |
21,151.17 | 3,243.68 |
| SUBTOTAL | 553,037.50 | 139,465.40 |
Sign in to see all competitors of Abivax Sa.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Abivax Sa versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Abivax Sa's Competitors Named by the Company
Competitive relationships identified from Abivax Sa reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| AbbVie | Company report | 85% |
| Roche | Company report | 85% |
| Merck | Company report | 85% |
| Teva/Sanofi | Company report | 85% |
| Eli Lilly | Company report | 85% |
| Pfizer | Company report | 85% |
| Agomab Therapeutics Nv | Company report | 85% |
| Johnson & Johnson | Company report | 85% |
| Takeda | Company report | 85% |
| Roivant | Company report | 85% |
Company report basis, confidence, active dates and source counts for Abivax Sa's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Abivax Sa's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Pfizer Inc | U.S. Commercial Division 58.35 % |
| Arcus Biosciences Inc | Reportable 100.00 % |
| Vir Biotechnology Inc | Reportable -100.00 % |
| Immunome Inc | Single reportable segment 100.00 % |
| Novavax inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Abivax Sa's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Abivax Sa | 6,049 | - | -34,545,835 |
| Pfizer Inc | 168,102 | 848,333 | 54,160 |
| Bristol myers Squibb Company | 127,573 | 1,539,477 | 284,338 |
| Moderna Inc | 107,062 | 474,043 | -670,426 |
| Regeneron Pharmaceuticals Inc | 97,148 | 1,096,444 | 312,615 |
| Biontech Se | 21,151 | 415,483 | -164,532 |
| PEERS TOTAL | 546,989 | 978,890 | 75,870 |
Abivax Sa's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Pfizer Inc | United States 63.93 % |
| Bristol myers Squibb Company | United States 69.43 % |
| Novavax inc | United States 68.88 % |
| Opko Health Inc | IE 27.07 % |
| Siga Technologies Inc | US 100.00 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Abivax Sa's Position in Industry Market Structure
Market-capitalization share and concentration across all 495 companies in Abivax Sa's industry classification, broader than the peer set above. Market cap in millions of $.Abivax Sa ranks #52 of 495 companies by market capitalization in its industry, holding 0.10 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 888, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,261,743 | 21.10 % |
| 2 | Johnson and Johnson | 688,377 | 11.51 % |
| 3 | Beone Medicines Ltd | 628,233 | 10.51 % |
| 4 | Abbvie Inc | 519,434 | 8.69 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 52 | Abivax Sa | 6,049 | 0.10 % |
Market cap and industry share for the rest of Abivax Sa's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-09.
Abivax Sa's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 47 | Redhill Biopharma Ltd | 7,122 | -67.65 % |
| 48 | Arrowhead Pharmaceuticals Inc | 7,060 | 24.33 % |
| 49 | Amneal Pharmaceuticals Inc | 6,982 | 75.04 % |
| 50 | Axsome Therapeutics Inc | 6,939 | -4.52 % |
| 51 | Ligand Pharmaceuticals Incorporated | 1,234 | 12.3% |
| 52 | Abivax Sa | 6,049 | -17.05 % |
| 53 | Ptc Therapeutics inc | 1,234 | 12.3% |
| 54 | Mirum Pharmaceuticals Inc | 1,234 | 12.3% |
| 55 | Veradermics Inc | 1,234 | 12.3% |
| 56 | Cogent Biosciences Inc | 1,234 | 12.3% |
| 57 | Belite Bio Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Abivax Sa's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-09. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Abivax Sa's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (445 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.6x | - |
| EV / EBITDA | - | 15.5x | - |
| P/B | 14.2x | 4.3x | +9.9x |
| Return on Equity | -71.13 % | industry aggregate | -91.25 % |
| Return on Invested Capital | -25.54 % | -9.84 % (avg) | -15.70 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Abivax Sa's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Abivax Sa falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.1% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Abivax Sa's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 888 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Abivax Sa's dedicated Suppliers and Customers pages, not here.
Abivax Sa's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Abivax Sa falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Abivax Sa's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 91.3 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
- A meaningful share of competitors (65.30 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Abivax Sa's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Abivax Sa | 8.20 | 8.75 | - |
| Pfizer Inc | 0.04 | 1.27 | 0.72 |
| Bristol myers Squibb Company | 0.48 | 1.44 | 2.12 |
| Moderna Inc | 0.86 | 2.88 | 0.07 |
| Regeneron Pharmaceuticals Inc | 0.58 | 3.56 | 0.06 |
| Biontech Se | 3.58 | 7.54 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Abivax Sa's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Abivax Sa | Q4 2025 | - | - |
| Pfizer Inc | Q3 2026 | -0.4 % | -8.7 % |
| Bristol myers Squibb Company | Q3 2026 | +6.9 % | -1.5 % |
| Moderna Inc | Q2 2026 | +2.1 % | - |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +36.3 % | +33.5 % |
| Biontech Se | Q4 2025 | +9.0 % | - |
| PEERS TOTAL | +7.9 % | +1.8 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Abivax Sa's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Abivax Sa | Q4 2025 | - | -76.8 % |
| Pfizer Inc | Q3 2026 | -3.5 % | -4.8 % |
| Bristol myers Squibb Company | Q3 2026 | +20.7 % | +7.5 % |
| Moderna Inc | Q2 2026 | -21.8 % | +1,133.3 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +104.1 % | +49.1 % |
| Biontech Se | Q4 2025 | +23.9 % | -36.1 % |
Abivax Sa's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Abivax Sa | - | - | - |
| Pfizer Inc | 1.98% | 2.34% | 4.62% |
| Bristol myers Squibb Company | 10.47% | 13.59% | 43.83% |
| Moderna Inc | - | - | - |
| Regeneron Pharmaceuticals Inc | 11.50% | 13.00% | 15.07% |
| Biontech Se | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Abivax Sa's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Abivax Sa | - | - |
| Pfizer Inc | 41.60 | 2.64 |
| Bristol myers Squibb Company | 13.77 | 2.55 |
| Moderna Inc | - | 48.05 |
| Regeneron Pharmaceuticals Inc | 20.35 | 5.75 |
| Biontech Se | - | 6.52 |
| PEERS AVERAGE | 53.03 | 3.97 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.